Fulphila, co-developed by Biocon Biologics and Mylan, was the first
biosimilar pegfilgrastim to be approved in the US and was launched in
July 2018.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-mylan-launch-cancer-drug-in-canada/articleshow/75434205.cms
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment